The legal pathway to MDMA-assisted therapy in Canada has one door: Health Canada's Special Access Program (SAP). The January 5, 2022 SAP amendment added MDMA (alongside psilocybin) to practitioner-initiated SAP eligibility for patients with serious or life-threatening conditions where conventional treatments have failed. Patients cannot apply directly. The dominant approved indication is PTSD — driven by the strongest published RCT evidence in psychedelic medicine (Mitchell 2021 MAPP1 and Mitchell 2023 MAPP2 Nature Medicine Phase 3 trials). Canadian SAP MDMA approvals were running roughly a quarter of psilocybin volume — approximately 41 MDMA approvals as of February 2024 versus ~176 psilocybin — and PsyCan reported a sharp decline in approvals across both substances through 2025. The August 2024 FDA Complete Response Letter on Lykos Therapeutics' MDMA-AT for PTSD application has not changed the Canadian SAP-pathway operational reality, but it has added regulatory uncertainty about future formal Canadian approval. This article walks through the access pathway honestly.

Key takeaways

The Health Canada Special Access Program (SAP) is the only legal pathway to MDMA-AT in Canada. The January 5, 2022 amendment created the practitioner-initiated framework.

Patients cannot apply directly. A licensed physician or nurse practitioner submits a case-specific MDMA SAP request on behalf of an individual patient.

PTSD is the dominant approved indication — supported by Mitchell 2021 MAPP1 and Mitchell 2023 MAPP2 Phase 3 trials. Other indications (autistic-adult social anxiety, eating disorders, couples therapy with PTSD) are uncommon SAP cases.

Documentation requirements: failed first-line PTSD treatments (trauma-focused CBT, prolonged exposure, EMDR; SSRIs/SNRIs at therapeutic dose for ≥6 weeks).

Statistics: ~41 MDMA SAP approvals as of February 2024 (vs ~176 psilocybin); PsyCan reported sharp decline through 2025 across both substances; review timelines lengthened.

Drug supply: Lykos-supplied pharmaceutical-grade MDMA via clinical-trial pathways or imported supply — the supply chain is more constrained than psilocybin's (no Filament-equivalent at scale).

The August 2024 FDA decision on Lykos's MDMA-AT for PTSD application does not change the Canadian SAP pathway operationally but adds regulatory uncertainty about future formal approval.

ATMA CENA supports preparation and integration for SAP-pathway MDMA-AT patients via coordinated care. The medical SAP application is initiated by the patient's prescribing physician.

Veterans Affairs Canada considers MDMA-AT case-by-case for service-related PTSD where SAP-approved.

The legal framework — same SAP architecture as psilocybin

MDMA's Canadian regulatory framework mirrors psilocybin's, with one key difference: MDMA is Schedule I under the CDSA (more restrictive than psilocybin's Schedule III). The practical access pathway is the same.

Pre-2022 — Section 56(1) exemptions for psilocybin (not MDMA)

The August 2020 Section 56(1) exemptions for four terminally ill Canadians applied to psilocybin specifically, not MDMA. MDMA-AT therapeutic access in Canada was not established at the Section 56 level before the SAP amendment.

January 5, 2022 — SAP amendment (durable pathway for both)

The Health Canada amendment to the Food and Drug Regulations expanded SAP eligibility to include both psilocybin and MDMA for serious or life-threatening conditions where conventional treatments have failed. See the Health Canada SAP psychedelic-assisted psychotherapy notice.

Provincial regulator framework

Provincial colleges have not generally issued specific MDMA policies. Off-label MDMA prescribing outside SAP is highly unusual and likely subject to college review. Quebec's Bill 21 reserved-act psychotherapy applies for the psychotherapy component.

For the broader regulatory deep dive applicable to both substances, see Health Canada SAP for Psilocybin — the regulatory architecture is the same.

Who is typically eligible? PTSD focus

Health Canada SAP authorizations for MDMA are case-specific and overwhelmingly target PTSD.

PTSD — the dominant indication

The published evidence strongly supports MDMA-AT for PTSD (Mitchell 2021 MAPP1, Mitchell 2023 MAPP2 Nature Medicine Phase 3). Canadian SAP applications for PTSD typically include:

DSM-5 PTSD diagnosis with documented severity
Documented failure of first-line treatments:
- Trauma-focused cognitive-behavioural therapy (TF-CBT)
- Prolonged exposure therapy (PE)
- Eye movement desensitization and reprocessing (EMDR)
- SSRIs/SNRIs at therapeutic dose for ≥6 weeks
Documentation of ongoing functional impairment — work, relationships, daily functioning
Comorbidity considerations — depression, anxiety, substance use disorder (active SUD typically requires stabilization first)

Service-related PTSD

A meaningful subset of Canadian MDMA SAP applications target service-related PTSD in veterans, first responders (police, paramedics, firefighters), and corrections officers. The Mithoefer 2018 Lancet Psychiatry Phase 2 RCT specifically enrolled this population (military veterans, firefighters, police) and demonstrated efficacy.

For veterans pursuing the SAP pathway with VAC coverage support, see MDMA-Assisted Therapy for Veterans (Wave 2 sibling article).

Other indications — uncommon SAP

Autistic-adult social anxiety (Danforth 2018 small open-label evidence) — uncommon SAP cases
Couples therapy with PTSD (Monson 2020 ARROW evidence) — emerging
Eating disorders — research-stage; uncommon SAP

The realistic 2026 SAP MDMA pathway is PTSD-focused.

Common screening exclusions

Personal history of psychotic disorder (schizophrenia, schizoaffective, bipolar I)
Active mania or recent hypomania
Uncontrolled cardiovascular disease, recent MI, severe structural heart disease, significant arrhythmia
Pregnancy
Severe hepatic impairment
Concurrent MAOIs (absolute — serotonin syndrome and hypertensive crisis risk)
Active substance use disorder requiring stabilization
Inability to provide informed consent

The practical SAP application

The SAP application is physician- or NP-initiated — patients cannot apply directly. The 2026 process:

Step 1: Find a willing prescribing physician or NP

The bottleneck most patients face. Resources for finding willing prescribers:

TheraPsil — directory of trained Canadian clinicians; supports MDMA SAP applications alongside psilocybin work; free patient consultations
MAPS Canada — separate organization from Lykos (US-based); supports Canadian research, training, and advocacy for MDMA-AT
Numinus / Stella — multi-site presence with SAP-pathway support
Roots to Thrive (Nanaimo BC) — group-based KAT model with SAP-pathway expansion to MDMA-AT in development
Quebec collective — psychedelic-medicine clinicians with SAP-pathway experience
ATMA CENA's clinical team — does not initiate SAP applications but can discuss the regulatory framework and orient patients to appropriate resources

Step 2: Document failed conventional treatments

The SAP request requires documentation of which PTSD treatments have been tried, at what dose/duration, and why they failed, were unsuitable, or were unavailable. For PTSD specifically:

Trauma-focused psychotherapy attempts (TF-CBT, PE, EMDR) with details
Pharmacotherapy attempts (SSRIs, SNRIs at therapeutic dose for ≥6 weeks each)
Augmentation strategies (atypical antipsychotics, prazosin for nightmares, etc.) where applicable
Why these failed or were inadequate

Step 3: Submit the SAP request

The prescribing physician completes the SAP request form, identifies a drug source (typically Lykos clinical-trial supply or imported pharmaceutical MDMA), justifies the clinical rationale with peer-reviewed evidence (Mitchell 2021/2023 cites MAPP1/MAPP2 directly), and submits to Health Canada (typically by fax to 613-941-3194 or via the SAP portal).

Step 4: Wait for case-specific authorization

Approval timelines historically 1–4 weeks; lengthening through 2025. PsyCan reported approval rates declining through 2025. Plan for 2–8 weeks or longer in 2026.

Step 5: Source the drug

Once authorized, the prescribing physician sources pharmaceutical-grade MDMA. Supply chain is more constrained than psilocybin's:

Lykos Therapeutics has supplied MDMA for clinical trials and SAP-pathway use
Imported pharmaceutical MDMA through specific authorization
Note: Filament Health's no-charge SAP psilocybin supply does not have an MDMA equivalent at scale; MDMA drug cost is typically a meaningful portion of program cost

Step 6: Deliver the supervised three-session program

The MDMA-AT program is delivered under the prescribing physician's authorization, with the standard three-phase model: preparation (3 sessions), three dosing days over ~12 weeks (each ~6–8 hours), integration (3 sessions per dosing day = 9 total). The prescribing physician retains medical responsibility throughout.

Step 7: Submit Form C post-treatment

Standard Health Canada Form C reporting outcomes, adverse events, clinical observations.

Statistics — Canadian MDMA SAP through 2025

Canadian MDMA SAP approval volumes have been consistently smaller than psilocybin:

Period	Approximate MDMA SAP approvals
Cumulative through February 2024	~41
Cumulative through mid-2025	Higher but still meaningfully below psilocybin

Comparison to psilocybin: ~176 psilocybin SAP approvals as of February 2024; cumulative ~301 by mid-2025. The MDMA volume has consistently run roughly 20–25% of psilocybin volume.

Reasons for the lower MDMA SAP volume:

Indication scope: psilocybin SAP covers multiple indications (end-of-life distress, TRD, AUD, demoralization); MDMA SAP is essentially PTSD-only
Drug supply: Filament's no-charge psilocybin supply has no MDMA equivalent
Regulatory uncertainty: the August 2024 FDA Complete Response Letter on Lykos's MDMA-AT application has added some clinician hesitancy
PsyCan reported overall approval declines through 2025 affecting both substances

The Lykos / FDA context — what it means for Canadian patients

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) submitted a New Drug Application to the FDA for MDMA-assisted therapy for PTSD in 2024, based on the MAPP1 and MAPP2 Phase 3 trials. In August 2024, the FDA issued a Complete Response Letter declining approval, citing concerns about:

Trial design issues — particularly blinding integrity given MDMA's distinctive subjective effects (similar concerns affected psilocybin Phase 3 designs)
Allegations of clinical-site misconduct at certain MAPP1 sites
The need for additional studies before reconsidering approval

Lykos has indicated it will pursue additional Phase 3 trials. The Canadian regulatory situation:

Canadian SAP pathway access continues — the FDA decision is US-specific and does not change Canadian regulatory operations
Health Canada operates independently from the FDA but typically reviews similar evidence; a future Canadian Notice of Compliance for MDMA-AT remains contingent on additional Phase 3 work and a successful submission
Clinical evidence remains strong — the Mitchell 2021/2023 trials are still peer-reviewed Phase 3 trials with substantial effect sizes; the FDA decision was about regulatory standards rather than fundamental efficacy questioning
Practical effect for Canadian patients: SAP-pathway MDMA-AT remains the legal access route. Future formal Canadian approval timeline is uncertain.

The honest 2026 framing for patients pursuing MDMA-AT in Canada: the SAP pathway is real and operational despite the global regulatory turbulence; future formal approval would expand access but is not on a defined timeline.

How ATMA CENA supports SAP-pathway MDMA-AT patients

ATMA CENA's role is the same as for psilocybin SAP-pathway work:

ATMA CENA does not initiate SAP applications. The medical SAP request is initiated by the patient's prescribing physician or nurse practitioner.
ATMA CENA supports preparation and integration through the three-phase psychedelic-assisted therapy model. For MDMA specifically, this includes the more extensive preparation and integration appropriate to a three-session protocol (~9 integration sessions plus 3 preparation sessions across the program).
The coordinated care model lets the patient's existing therapist remain the primary therapeutic relationship — particularly valuable for trauma-focused work where existing therapeutic alliance often runs deep — while ATMA CENA's clinical infrastructure provides the dosing-specific frame.
ATMA CENA's training program prepares clinicians for psychedelic-assisted therapy work; MDMA-AT-specific training scope should be confirmed at intake.

Frequently asked questions

Can I apply for SAP myself as a patient? No. SAP applications are physician- or nurse-practitioner-initiated. You need a willing prescriber.

How do I find a physician willing to apply for MDMA SAP? TheraPsil maintains a directory and offers free patient consultations. MAPS Canada supports Canadian MDMA-AT advocacy. Numinus, Roots to Thrive, and Quebec providers have SAP-pathway experience. ATMA CENA's intake call can orient you to appropriate resources.

What's the typical review timeline? Historically 1–4 weeks; lengthening through 2025. Plan for 2–8 weeks or longer in 2026.

Has MDMA-AT been approved by Health Canada? No, as of 2026. SAP is the only legal therapeutic pathway. The August 2024 FDA Complete Response Letter on Lykos's application has added uncertainty about formal Canadian approval timeline.

What conditions are SAP-approved for? PTSD overwhelmingly. Other indications (autistic-adult social anxiety, couples therapy with PTSD, eating disorders) are uncommon SAP cases.

Where does the drug come from? Pharmaceutical-grade MDMA from Lykos clinical-trial supply or imported through specific Health Canada authorization. Supply chain is more constrained than psilocybin's.

Does VAC cover MDMA-AT for veterans? Veterans Affairs Canada considers MDMA-AT case-by-case for service-related PTSD where SAP-approved. Coverage is not automatic; specific case review applies. See MDMA-Assisted Therapy for Veterans.

Does private insurance cover MDMA-AT? Generally no. Drug not covered (Schedule I, no approved indication). Therapy fees (preparation/integration) may be partially covered as standard psychotherapy. Alberta Blue Cross PAT (March 2024) covered ketamine; MDMA was framed as future potential.

Does Quebec RAMQ cover MDMA-AT? The December 2022 Farzin/Stephan RAMQ precedent was psilocybin-specific. Quebec has not extended the precedent to MDMA at this time. Quebec MDMA-AT patients face standard out-of-pocket costs.

What's the SAP approval rate for MDMA? Historical approval rates for SAP overall ran around 78% per industry reporting through 2024. PsyCan reported sharp decline through 2025 affecting both psilocybin and MDMA. Cumulative MDMA approvals reached ~41 by February 2024 and have grown more slowly since.

What if my SAP application is denied? Options include resubmitting with additional documentation, identifying a different prescriber, or pursuing alternative PTSD treatments. Ketamine therapy is the most accessible alternative with substantial published PTSD evidence (Feder 2014/2021 RCTs) and broader Canadian access pathways. See Ketamine Therapy for PTSD.

Can a nurse practitioner apply for MDMA SAP? Yes. The January 2022 amendment authorized both physicians and nurse practitioners to submit SAP requests for MDMA and psilocybin.

Will MDMA-AT eventually be approved in Canada? Possibly, depending on additional Phase 3 trial outcomes Lykos is pursuing and a future Health Canada submission. Approval would substantially expand access. Timeline is uncertain.

What if my indication isn't PTSD? SAP applications for non-PTSD MDMA indications are uncommon. Smaller signals exist for autistic-adult social anxiety (Danforth 2018), couples therapy with PTSD (Monson 2020 ARROW), and eating disorders. Discuss with your prescribing physician whether the case-specific evidence supports a SAP application.

Sources

ATMA CENA — coordinated care: https://psychedelic.healthcare/find-care
Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Government of Canada — MDMA / Ecstasy: https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/mdma.html
Mitchell JM, et al. (2021). MDMA-assisted therapy for severe PTSD: MAPP1. Nat Med. https://pubmed.ncbi.nlm.nih.gov/33972795/
Mitchell JM, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: MAPP2. Nat Med. https://pubmed.ncbi.nlm.nih.gov/37709999/
Mithoefer MC, et al. (2018). Phase 2 RCT in military veterans, firefighters, police. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29728331/
TheraPsil: https://therapsil.ca/
MAPS Canada: https://www.mapscanada.org/
PsyCan — Sharp decline in SAP approvals (September 2025): https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
FDA Complete Response Letter on MDMA-AT for PTSD (August 2024): https://www.psychiatrictimes.com/view/fda-releases-complete-response-letter-on-declining-mdma-assisted-therapy-for-ptsd

How to Access MDMA-Assisted Therapy in Canada

MDMA-assisted therapy remains investigational in many places